McAfee Receives AV-Comparatives Gold Awards for Best Real-World Protection and Best Performance Throughout 2024
20.1.2025 14:00:00 CET | Business Wire | Press release
Coveted awards celebrate McAfee for providing powerful malware protection without slowing down PCs
McAfee, a global online protection leader, today announced that it has been recognized by AV-Comparatives with both the ‘Real-World Protection Gold Award’ and the ‘Best Overall Speed Gold Award’. These honors spotlight McAfee’s unmatched ability to deliver top-tier malware protection to consumers while improving PC performance, as demonstrated in AV-Comparatives’ 2024 test results.
McAfee was one of only six vendors to achieve top overall results in the 2024 Real-World Protection tests, while also ranking as the vendor with the lowest impact on PC performance throughout 2024. This means that by replacing the protection that comes with your PC’s operating system, McAfee can improve the overall performance of a PC.
This is particularly important at a time when bad actors are leveraging rapidly evolving and increasingly sophisticated tools to target victims.
Throughout the year, the AV-Comparatives Lab team rigorously tests leading consumer security products and evaluates them in terms of protection, and impact on PC performance.
- McAfee’s win in the Real-World Protection Test points to an ability to offer exceptional malware protection in everyday online conditions, as tested by AV-Comparatives. This recognition highlights McAfee’s success in providing a high level of protection with minimal false alarms; this ensures consumers are protected without the burden of discerning whether or not something is harmful.
- McAfee’s top rank in the PC Performance Test reflects its strength, as tested by AV-Comparatives, in delivering powerful security without slowing down system performance. This critical metric aligns with McAfee’s consumer-first focus, ensuring that consumers stay protected while their PCs run efficiently at top speed.
“We are honored to receive both the Best Real-World Protection and the Best PC Performance awards,” said Steve Grobman, Chief Technology Officer, McAfee. “AV-Comparatives’ trusted analysis validates our success in developing technology that protects people while improving device performance. We are committed to giving consumers the education and tools they need to stay safe online while maintaining performance and ensuring that our protection evolves as quickly as the threat landscape.”
Those interested in protecting themselves and their families online with this year’s top-rated security software can download a free trial of McAfee Total Protection. This includes the company’s award-winning anti-malware technology, as well as scam detection, social privacy management, identity monitoring, Secure VPN, password management, and safe browsing capabilities for all-in-one protection.
McAfee’s award-winning, AI-powered anti-malware technology is included in McAfee Total Protection, McAfee+ Premium, McAfee+ Advanced, and McAfee+ Ultimate.
You can learn more about McAfee’s awards and recognition from AV-Comparatives here.
About McAfee
McAfee Corp. is a global leader in online protection for consumers. Focused on protecting people, not just devices, McAfee’s consumer solutions adapt to users’ needs in an always online world, empowering them to live securely through integrated, intuitive solutions that protect their families, communities, and businesses with the right security at the right moment. For more information, please visit https://www.McAfee.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250120474901/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 07:00:00 CET | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 07:00:00 CET | Press release
From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio® (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF® (trifarotene)1-8 Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil® in different skin types9 Data from Galderma’s Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane®, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and décolletage10-14 A total of 22 presentations will reinforce the value of Galderma’s broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare Galderma (SIX: GALD), the pure-play dermatology category leader, wi
Avanzanite Expands French Operations and Appoints Constance Sabbagh as General Manager24.3.2026 07:00:00 CET | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into France, Europe’s second largest economy, and the appointment of Constance Sabbagh as General Manager, France. Following a €32 million Series A investment by MVM Partners announced in November 2025, Avanzanite is scaling its European infrastructure into a single, integrated platform across 32 countries – designed to bring rare disease medicines to patients in every European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323639110/en/ Constance Sabbagh, General Manager, France “France is essential to Avanzanite’s European vision,” said Adam Plich, Co-founder and CEO of Avanzanite. “With its leadership in rare disease policy through its National Rare Disease Plans, care networks and scientific innovation, France is one of the most significant healthcare
HJS Foundation Releases JEP Protocol & HJS Framework: The "Black Box" for AI, Enabling Verifiable Human Oversight24.3.2026 04:36:00 CET | Press release
HJS Foundation (Human Judgment Systems Foundation) today released two complementary solutions: the Judgment Event Protocol (JEP) and the Human Judgment Structure (HJS) framework. As a minimalist open standard, JEP generates tamper-proof records of AI decision accountability, just like an aircraft black box; HJS embeds human judgment logic into AI operation processes — together, they transform "human oversight" from a regulatory requirement into a verifiable technical fact, providing an optional technical solution for AI accountability. How to prove that AI decisions (such as loan approvals, medical diagnoses, border screenings, etc.) have undergone human review? JEP generates immutable audit trails of human intervention through four cryptographic primitives — Judge, Verify, Delegate, Terminate; HJS builds a controllable and accountable system to prevent risks such as AI drift and ensure that human judgment guides AI operations. Current systems rely on alterable post-hoc documentation,
Power Integrations Extends Flyback Topology to Enable 440 W, Offering Simpler Alternatives to Resonant Power Designs23.3.2026 22:45:00 CET | Press release
New TOPSwitchGaN ICs more than double power output, reducing system cost, complexity, and design time APEC 2026 – Power Integrations (NASDAQ: POWI), the leader in high-voltage integrated circuits for energy-efficient power conversion, today introduced a breakthrough in flyback topology extending the power range of flyback converters to 440 W—well beyond the limits that traditionally required more complex resonant and LLC topologies. The new TOPSwitchGaN™ flyback IC family unites the company’s groundbreaking PowiGaN™ technology with its iconic TOPSwitch™ IC architecture, reducing complexity, eliminating heat sinks in many cases, shortening design time, improving manufacturability, and lowering total system cost. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323686299/en/ The new TOPSwitchGaN™ flyback IC family extends the power range of flyback converters to 440 W—well beyond the limits that traditionally required more co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom